• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

AI system beats radiologists at predicting lung cancer risk

Share:

May 28, 2019

A deep learning AI system was able to detect malignant lung nodules better than radiologists in a new study by Google and Northwestern University.

The system analyses low-dose chest computed tomography scans. It provides an automated image evaluation system to enhance the accuracy of early lung cancer diagnosis that could lead to earlier treatment.

The programme utilises both the primary CT scan and, whenever available, a prior CT scan from the patient as input. Prior CT scans are useful in predicting lung cancer malignancy risk because the growth rate of suspicious lung nodules can be indicative of malignancy.

The computer was trained using fully de-identified, biopsy-confirmed low-dose chest CT scans.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

It identifies both a region of interest and whether the region has a high likelihood of lung cancer.

The model outperformed six radiologists when previous CT imaging was not available and performed as well as the radiologists when there was prior imaging.

The system also produced fewer false positives and fewer false negatives, which could lead to fewer unnecessary follow-up procedures and fewer missed tumours if it were used in a clinical setting.

Google scientists developed the deep-learning model and applied it to 6,716 de-identified CT scan sets provided by Northwestern Medicine to validate the accuracy of its new system.

The scientists found the artificial-intelligence-powered system was able to spot sometimes-minuscule malignant lung nodules with a model area under the curve of 0.94 test cases.

“Radiologists generally examine hundreds of two-dimensional images or ‘slices’ in a single CT scan but this new machine learning system views the lungs in a huge, single three-dimensional image,” said study co-author Dr Mozziyar Etemadi, a research assistant professor of anesthesiology at Northwestern University Feinberg School of Medicine and of engineering at McCormick School of Engineering.

“AI in 3D can be much more sensitive in its ability to detect early lung cancer than the human eye looking at 2D images. This is technically ‘4D’ because it is not only looking at one CT scan, but two (the current and prior scan) over time.”

Etemadi added: “The system can categorise a lesion with more specificity. Not only can we better diagnose someone with cancer, we can also say if someone doesn’t have cancer, potentially saving them from an invasive, costly and risky lung biopsy.”

Date: May 28, 2019

Source: Pharma Phorum

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • UK Medical 3D Printing Startup axial3D Lands $3M to Support US ExpansionUK Medical 3D Printing Startup axial3D Lands $3M to Support US Expansion
  • Florence Acquires Virtual Care Solution ZipnosisFlorence Acquires Virtual Care Solution Zipnosis
  • U.S. hospitals pay as much as 6 times more for medical devices than European counterparts, study showsU.S. hospitals pay as much as 6 times more for medical devices than European counterparts, study shows
  • Health Benefits, Insurance Navigation Chatbot Sensely Lands $15MHealth Benefits, Insurance Navigation Chatbot Sensely Lands $15M
  • 65LAB Launches in Partnership with Evotec SE and Backed by Leading Global Investors to Advance Drug Discovery and New Company Creation in Singapore65LAB Launches in Partnership with Evotec SE and Backed by Leading Global Investors to Advance Drug Discovery and New Company Creation in Singapore
  • AstraZeneca, Eko Collaborate to Advance Innovation Around Heart FailureAstraZeneca, Eko Collaborate to Advance Innovation Around Heart Failure
  • Pear Therapeutics and Remedyone Announce Pharmacy Benefit Manager Coverage for Prescription Digital Therapeutics Reset® & Reset-o® for People with Substance and Opioid Use DisordersPear Therapeutics and Remedyone Announce Pharmacy Benefit Manager Coverage for Prescription Digital Therapeutics Reset® & Reset-o® for People with Substance and Opioid Use Disorders
  • Theratechnologies Acquires Targeted Oncology Company Katana Biopharma Inc.Theratechnologies Acquires Targeted Oncology Company Katana Biopharma Inc.

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications